Atara Biotherapeutics, Inc. (ATRA): Price and Financial Metrics


Atara Biotherapeutics, Inc. (ATRA): $4.89

-0.38 (-7.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATRA POWR Grades

  • Value is the dimension where ATRA ranks best; there it ranks ahead of 70.8% of US stocks.
  • ATRA's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • ATRA's current lowest rank is in the Stability metric (where it is better than 2.29% of US stocks).

ATRA Stock Summary

  • Of note is the ratio of ATARA BIOTHERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 9.15% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 148.52%, ATARA BIOTHERAPEUTICS INC's debt growth rate surpasses 91.22% of about US stocks.
  • As for revenue growth, note that ATRA's revenue has grown 454.25% over the past 12 months; that beats the revenue growth of 97.8% of US companies in our set.
  • Stocks that are quantitatively similar to ATRA, based on their financial statements, market capitalization, and price volatility, are ARCT, CRNX, RNA, PTGX, and AFMD.
  • ATRA's SEC filings can be seen here. And to visit ATARA BIOTHERAPEUTICS INC's official web site, go to www.atarabio.com.

ATRA Valuation Summary

  • ATRA's price/sales ratio is 5.2; this is 153.66% higher than that of the median Healthcare stock.
  • Over the past 101 months, ATRA's EV/EBIT ratio has gone up 7.6.

Below are key valuation metrics over time for ATRA.

Stock Date P/S P/B P/E EV/EBIT
ATRA 2023-01-20 5.2 2.0 -1.5 -1.5
ATRA 2023-01-19 4.8 1.8 -1.4 -1.3
ATRA 2023-01-18 4.9 1.9 -1.4 -1.4
ATRA 2023-01-17 5.1 1.9 -1.5 -1.4
ATRA 2023-01-13 5.2 2.0 -1.5 -1.5
ATRA 2023-01-12 5.2 2.0 -1.5 -1.5

ATRA Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at -17.33%.
  • Its year over year cash and equivalents growth rate is now at -32.7%.
  • The 5 year net income to common stockholders growth rate now stands at -238.35%.
ATRA's revenue has moved up $70,900,000 over the prior 49 months.

The table below shows ATRA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 70.9 -247.819 -247.079
2022-06-30 71.811 -241.74 -247.652
2022-03-31 24.102 -239.353 -349.911
2021-12-31 20.34 -220.522 -340.141
2021-09-30 12.792 -190.373 -328.099
2021-06-30 7.422 -184.354 -317.783

ATRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATRA has a Quality Grade of C, ranking ahead of 37.13% of graded US stocks.
  • ATRA's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • HGEN, ARMP, and ZSAN are the stocks whose asset turnover ratios are most correlated with ATRA.

The table below shows ATRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.025 1 -1.135
2021-06-30 0.015 1 -1.059
2021-03-31 0.007 1 -0.973
2020-12-31 0.000 NA -1.036
2020-09-30 0.000 NA -1.093
2020-06-30 0.000 NA -1.152

ATRA Price Target

For more insight on analysts targets of ATRA, see our ATRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.38 Average Broker Recommendation 1.41 (Moderate Buy)

ATRA Stock Price Chart Interactive Chart >

Price chart for ATRA

ATRA Price/Volume Stats

Current price $4.89 52-week high $16.07
Prev. close $5.27 52-week low $2.83
Day low $4.78 Volume 893,600
Day high $5.22 Avg. volume 1,109,911
50-day MA $3.97 Dividend yield N/A
200-day MA $4.79 Market Cap 463.96M

Atara Biotherapeutics, Inc. (ATRA) Company Bio


Atara Biotherapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. The company was founded in 2012 and is based in South San Francisco, California.


ATRA Latest News Stream


Event/Time News Detail
Loading, please wait...

ATRA Latest Social Stream


Loading social stream, please wait...

View Full ATRA Social Stream

Latest ATRA News From Around the Web

Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif., January 13, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired emp

Yahoo | January 13, 2023

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif., January 04, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Fr

Yahoo | January 4, 2023

3 Under-the-Radar Biotech Stocks to Buy in 2022

Beam Therapeutics is different from many CRISPR-editing biotechs in that it uses ex-vivo base cell editing instead of nuclease cell editing. Beam stock is down more than 48% so far this year, but the company has a growing pipeline that shows promise. Its lead therapy is BEAM-101 to treat various blood diseases, including sickle cell disease (SCD) and beta thalassemia.

Yahoo | December 24, 2022

Atara (NASDAQ:ATRA) to Receive $31 Million to Propagate Epstein‑Barr Therapy

Clinical-stage therapeutics company Atara Biotherapeutics (NASDAQ:ATRA) recently entered a financing deal with investment firm HealthCare Royalty. …

TipRanks | December 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!

William White on InvestorPlace | December 20, 2022

Read More 'ATRA' Stories Here

ATRA Price Returns

1-mo 49.09%
3-mo 4.71%
6-mo 44.67%
1-year -68.16%
3-year -63.04%
5-year -86.40%
YTD 49.09%
2022 -79.19%
2021 -19.71%
2020 19.19%
2019 -52.59%
2018 91.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8417 seconds.